Evaluation of a novel vesicular stomatitis virus pseudotype‐based assay for detection of neutralizing antibody responses to SARS‐CoV
Identifieur interne : 004285 ( Main/Exploration ); précédent : 004284; suivant : 004286Evaluation of a novel vesicular stomatitis virus pseudotype‐based assay for detection of neutralizing antibody responses to SARS‐CoV
Auteurs : Shuetsu Fukushi [Japon] ; Tetsuya Mizutani [Japon] ; Masayuki Saijo [Japon] ; Ichiro Kurane [Japon] ; Fumihiro Taguchi [Japon] ; Masato Tashiro [Japon] ; Shigeru Morikawa [Japon]Source :
- Journal of Medical Virology [ 0146-6615 ] ; 2006-12.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (sang), Cellules Vero, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (génétique), Glycoprotéines membranaires (immunologie), Glycoprotéines membranaires (métabolisme), Humains, Protéines de l'enveloppe virale (génétique), Protéines de l'enveloppe virale (immunologie), Protéines de l'enveloppe virale (métabolisme), Recombinaison génétique, Sensibilité et spécificité, Syndrome respiratoire aigu sévère (diagnostic), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (virologie), Tests de neutralisation, Virus de la stomatite vésiculeuse de type Indiana (génétique), Virus de la stomatite vésiculeuse de type Indiana (immunologie), Virus du SRAS (génétique), Virus du SRAS (immunologie), Virus du SRAS (métabolisme).
- MESH :
- diagnostic : Syndrome respiratoire aigu sévère.
- génétique : Glycoprotéines membranaires, Protéines de l'enveloppe virale, Virus de la stomatite vésiculeuse de type Indiana, Virus du SRAS.
- immunologie : Glycoprotéines membranaires, Protéines de l'enveloppe virale, Syndrome respiratoire aigu sévère, Virus de la stomatite vésiculeuse de type Indiana, Virus du SRAS.
- métabolisme : Glycoprotéines membranaires, Protéines de l'enveloppe virale, Virus du SRAS.
- sang : Anticorps antiviraux.
- virologie : Syndrome respiratoire aigu sévère.
- Pascal (Inist)
- MESH :
English descriptors
- KwdEn :
- Animals, Antibodies, Viral (blood), Chlorocebus aethiops, Detection, Humans, Humoral immunity, Immune response, Membrane Glycoproteins (genetics), Membrane Glycoproteins (immunology), Membrane Glycoproteins (metabolism), Method, Neutralization, Neutralization Tests, Neutralizing antibody, Recombination, Genetic, SARS Virus (genetics), SARS Virus (immunology), SARS Virus (metabolism), Sensitivity and Specificity, Severe Acute Respiratory Syndrome (diagnosis), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (virology), Severe acute respiratory syndrome, Severe acute respiratory syndrome virus, Spike Glycoprotein, Coronavirus, Vero Cells, Vesicular stomatitis Indiana virus (genetics), Vesicular stomatitis Indiana virus (immunology), Vesicular stomatitis virus, Viral Envelope Proteins (genetics), Viral Envelope Proteins (immunology), Viral Envelope Proteins (metabolism).
- MESH :
- chemical , blood : Antibodies, Viral.
- chemical , genetics : Membrane Glycoproteins, Viral Envelope Proteins.
- chemical , immunology : Membrane Glycoproteins, Viral Envelope Proteins.
- chemical , metabolism : Membrane Glycoproteins, Viral Envelope Proteins.
- diagnosis : Severe Acute Respiratory Syndrome.
- genetics : SARS Virus, Vesicular stomatitis Indiana virus.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome, Vesicular stomatitis Indiana virus.
- metabolism : SARS Virus.
- virology : Severe Acute Respiratory Syndrome.
- Teeft :
- Animals, Antibody titers, Assay, Biochem biophys, Causative agent, Cell tropism, Chlorocebus aethiops, Conventional neutralization assay, Coronavirus, Fukushi, Good correlation, Healthcare workers, Highest dilution, Hong kong, Humans, Infectious diseases, Infectious progeny virus, Infectivity, Japan society, Major target, Malik peiris, Nabs, National institute, Neutralization, Neutralization Tests, Neutralization assay, Neutralizing, Present study, Pseudotype, Rapid detection, Recombination, Genetic, Respiratory syndrome coronavirus, Sars, Sars coronavirus, Sars epidemic, Sensitivity and Specificity, Serum dilution, Serum sample, Serum samples, Spike Glycoprotein, Coronavirus, Stomatitis virus, Titer, Useful tool, Vero, Vero Cells.
Abstract
Severe acute respiratory syndrome (SARS)‐coronavirus (SARS‐CoV) is the causative agent of SARS. The S protein of SARS‐CoV is a major target for neutralizing antibodies (Nabs) in infected patients. We developed a neutralization assay using a recombinant vesicular stomatitis virus (VSV) bearing SARS‐CoV‐S protein (VSV‐SARS‐St19). A total of 56 serum samples collected from 22 healthcare workers in the Hanoi French Hospital during the SARS epidemic in 2003 were evaluated and compared to the conventional neutralizing assay using infectious SARS‐CoV. The results of the neutralization assay using VSV‐SARS‐St19 pseudotype showed good correlations with those using infectious SARS‐CoV. The newly developed neutralization assay was more sensitive to low antibody titers in serum samples. Thus, the VSV‐SARS‐St19 is a useful tool for detecting Nabs against SARS‐CoV. J. Med. Virol. 78:1509–1512, 2006. © 2006 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/jmv.20732
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000122
- to stream Istex, to step Curation: 000122
- to stream Istex, to step Checkpoint: 001711
- to stream PubMed, to step Corpus: 002006
- to stream PubMed, to step Curation: 002006
- to stream PubMed, to step Checkpoint: 002200
- to stream Ncbi, to step Merge: 001748
- to stream Ncbi, to step Curation: 001748
- to stream Ncbi, to step Checkpoint: 001748
- to stream Main, to step Merge: 004501
- to stream PascalFrancis, to step Corpus: 000435
- to stream PascalFrancis, to step Curation: 000555
- to stream PascalFrancis, to step Checkpoint: 000481
- to stream Main, to step Merge: 004682
- to stream Main, to step Curation: 004285
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluation of a novel vesicular stomatitis virus pseudotype‐based assay for detection of neutralizing antibody responses to SARS‐CoV</title><author><name sortKey="Fukushi, Shuetsu" sort="Fukushi, Shuetsu" uniqKey="Fukushi S" first="Shuetsu" last="Fukushi">Shuetsu Fukushi</name></author><author><name sortKey="Mizutani, Tetsuya" sort="Mizutani, Tetsuya" uniqKey="Mizutani T" first="Tetsuya" last="Mizutani">Tetsuya Mizutani</name></author><author><name sortKey="Saijo, Masayuki" sort="Saijo, Masayuki" uniqKey="Saijo M" first="Masayuki" last="Saijo">Masayuki Saijo</name></author><author><name sortKey="Kurane, Ichiro" sort="Kurane, Ichiro" uniqKey="Kurane I" first="Ichiro" last="Kurane">Ichiro Kurane</name></author><author><name sortKey="Taguchi, Fumihiro" sort="Taguchi, Fumihiro" uniqKey="Taguchi F" first="Fumihiro" last="Taguchi">Fumihiro Taguchi</name></author><author><name sortKey="Tashiro, Masato" sort="Tashiro, Masato" uniqKey="Tashiro M" first="Masato" last="Tashiro">Masato Tashiro</name></author><author><name sortKey="Morikawa, Shigeru" sort="Morikawa, Shigeru" uniqKey="Morikawa S" first="Shigeru" last="Morikawa">Shigeru Morikawa</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E4E287284BC9B9C90C9C129E00637D69B0F35C14</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/jmv.20732</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-77CNW51P-Q/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000122</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000122</idno><idno type="wicri:Area/Istex/Curation">000122</idno><idno type="wicri:Area/Istex/Checkpoint">001711</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001711</idno><idno type="wicri:doubleKey">0146-6615:2006:Fukushi S:evaluation:of:a</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:17063504</idno><idno type="wicri:Area/PubMed/Corpus">002006</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002006</idno><idno type="wicri:Area/PubMed/Curation">002006</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002006</idno><idno type="wicri:Area/PubMed/Checkpoint">002200</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002200</idno><idno type="wicri:Area/Ncbi/Merge">001748</idno><idno type="wicri:Area/Ncbi/Curation">001748</idno><idno type="wicri:Area/Ncbi/Checkpoint">001748</idno><idno type="wicri:doubleKey">0146-6615:2006:Fukushi S:evaluation:of:a</idno><idno type="wicri:Area/Main/Merge">004501</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:06-0526209</idno><idno type="wicri:Area/PascalFrancis/Corpus">000435</idno><idno type="wicri:Area/PascalFrancis/Curation">000555</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000481</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000481</idno><idno type="wicri:doubleKey">0146-6615:2006:Fukushi S:evaluation:of:a</idno><idno type="wicri:Area/Main/Merge">004682</idno><idno type="wicri:Area/Main/Curation">004285</idno><idno type="wicri:Area/Main/Exploration">004285</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Evaluation of a novel vesicular stomatitis virus pseudotype‐based assay for detection of neutralizing antibody responses to SARS‐CoV</title><author><name sortKey="Fukushi, Shuetsu" sort="Fukushi, Shuetsu" uniqKey="Fukushi S" first="Shuetsu" last="Fukushi">Shuetsu Fukushi</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Virology I, National Institute of Infectious Diseases, Musashimurayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Japon</country></affiliation><affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">Japon</country><wicri:regionArea>Correspondence address: Special Pathogens Laboratory, Department of Virology I, National Institute of Infectious Diseases, Gakuen 4‐7‐1, Musashimurayama, Tokyo 208‐0011</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Mizutani, Tetsuya" sort="Mizutani, Tetsuya" uniqKey="Mizutani T" first="Tetsuya" last="Mizutani">Tetsuya Mizutani</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Virology I, National Institute of Infectious Diseases, Musashimurayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Saijo, Masayuki" sort="Saijo, Masayuki" uniqKey="Saijo M" first="Masayuki" last="Saijo">Masayuki Saijo</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Virology I, National Institute of Infectious Diseases, Musashimurayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Kurane, Ichiro" sort="Kurane, Ichiro" uniqKey="Kurane I" first="Ichiro" last="Kurane">Ichiro Kurane</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Virology I, National Institute of Infectious Diseases, Musashimurayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Taguchi, Fumihiro" sort="Taguchi, Fumihiro" uniqKey="Taguchi F" first="Fumihiro" last="Taguchi">Fumihiro Taguchi</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Virology III, National Institute of Infectious Diseases, Musashimurayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Tashiro, Masato" sort="Tashiro, Masato" uniqKey="Tashiro M" first="Masato" last="Tashiro">Masato Tashiro</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Virology III, National Institute of Infectious Diseases, Musashimurayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Morikawa, Shigeru" sort="Morikawa, Shigeru" uniqKey="Morikawa S" first="Shigeru" last="Morikawa">Shigeru Morikawa</name><affiliation wicri:level="3"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Virology I, National Institute of Infectious Diseases, Musashimurayama, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Medical Virology</title><title level="j" type="alt">JOURNAL OF MEDICAL VIROLOGY</title><idno type="ISSN">0146-6615</idno><idno type="eISSN">1096-9071</idno><imprint><biblScope unit="vol">78</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1509">1509</biblScope><biblScope unit="page" to="1512">1512</biblScope><biblScope unit="page-count">4</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-12">2006-12</date></imprint><idno type="ISSN">0146-6615</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0146-6615</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Viral (blood)</term><term>Chlorocebus aethiops</term><term>Detection</term><term>Humans</term><term>Humoral immunity</term><term>Immune response</term><term>Membrane Glycoproteins (genetics)</term><term>Membrane Glycoproteins (immunology)</term><term>Membrane Glycoproteins (metabolism)</term><term>Method</term><term>Neutralization</term><term>Neutralization Tests</term><term>Neutralizing antibody</term><term>Recombination, Genetic</term><term>SARS Virus (genetics)</term><term>SARS Virus (immunology)</term><term>SARS Virus (metabolism)</term><term>Sensitivity and Specificity</term><term>Severe Acute Respiratory Syndrome (diagnosis)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Severe acute respiratory syndrome</term><term>Severe acute respiratory syndrome virus</term><term>Spike Glycoprotein, Coronavirus</term><term>Vero Cells</term><term>Vesicular stomatitis Indiana virus (genetics)</term><term>Vesicular stomatitis Indiana virus (immunology)</term><term>Vesicular stomatitis virus</term><term>Viral Envelope Proteins (genetics)</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Envelope Proteins (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux (sang)</term><term>Cellules Vero</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires (génétique)</term><term>Glycoprotéines membranaires (immunologie)</term><term>Glycoprotéines membranaires (métabolisme)</term><term>Humains</term><term>Protéines de l'enveloppe virale (génétique)</term><term>Protéines de l'enveloppe virale (immunologie)</term><term>Protéines de l'enveloppe virale (métabolisme)</term><term>Recombinaison génétique</term><term>Sensibilité et spécificité</term><term>Syndrome respiratoire aigu sévère (diagnostic)</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Tests de neutralisation</term><term>Virus de la stomatite vésiculeuse de type Indiana (génétique)</term><term>Virus de la stomatite vésiculeuse de type Indiana (immunologie)</term><term>Virus du SRAS (génétique)</term><term>Virus du SRAS (immunologie)</term><term>Virus du SRAS (métabolisme)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>SARS Virus</term><term>Vesicular stomatitis Indiana virus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Virus de la stomatite vésiculeuse de type Indiana</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Syndrome respiratoire aigu sévère</term><term>Virus de la stomatite vésiculeuse de type Indiana</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term><term>Vesicular stomatitis Indiana virus</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Anticorps neutralisant</term><term>Détection</term><term>Immunité humorale</term><term>Méthode</term><term>Neutralisation</term><term>Réponse immune</term><term>Syndrome respiratoire aigu sévère</term><term>Virus stomatite vésiculeuse</term><term>Virus syndrome respiratoire aigu sévère</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Animals</term><term>Antibody titers</term><term>Assay</term><term>Biochem biophys</term><term>Causative agent</term><term>Cell tropism</term><term>Chlorocebus aethiops</term><term>Conventional neutralization assay</term><term>Coronavirus</term><term>Fukushi</term><term>Good correlation</term><term>Healthcare workers</term><term>Highest dilution</term><term>Hong kong</term><term>Humans</term><term>Infectious diseases</term><term>Infectious progeny virus</term><term>Infectivity</term><term>Japan society</term><term>Major target</term><term>Malik peiris</term><term>Nabs</term><term>National institute</term><term>Neutralization</term><term>Neutralization Tests</term><term>Neutralization assay</term><term>Neutralizing</term><term>Present study</term><term>Pseudotype</term><term>Rapid detection</term><term>Recombination, Genetic</term><term>Respiratory syndrome coronavirus</term><term>Sars</term><term>Sars coronavirus</term><term>Sars epidemic</term><term>Sensitivity and Specificity</term><term>Serum dilution</term><term>Serum sample</term><term>Serum samples</term><term>Spike Glycoprotein, Coronavirus</term><term>Stomatitis virus</term><term>Titer</term><term>Useful tool</term><term>Vero</term><term>Vero Cells</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cellules Vero</term><term>Glycoprotéine de spicule des coronavirus</term><term>Humains</term><term>Recombinaison génétique</term><term>Sensibilité et spécificité</term><term>Tests de neutralisation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS)‐coronavirus (SARS‐CoV) is the causative agent of SARS. The S protein of SARS‐CoV is a major target for neutralizing antibodies (Nabs) in infected patients. We developed a neutralization assay using a recombinant vesicular stomatitis virus (VSV) bearing SARS‐CoV‐S protein (VSV‐SARS‐St19). A total of 56 serum samples collected from 22 healthcare workers in the Hanoi French Hospital during the SARS epidemic in 2003 were evaluated and compared to the conventional neutralizing assay using infectious SARS‐CoV. The results of the neutralization assay using VSV‐SARS‐St19 pseudotype showed good correlations with those using infectious SARS‐CoV. The newly developed neutralization assay was more sensitive to low antibody titers in serum samples. Thus, the VSV‐SARS‐St19 is a useful tool for detecting Nabs against SARS‐CoV. J. Med. Virol. 78:1509–1512, 2006. © 2006 Wiley‐Liss, Inc.</div></front></TEI><affiliations><list><country><li>Japon</li></country><region><li>Région de Kantō</li></region><settlement><li>Tokyo</li></settlement></list><tree><country name="Japon"><region name="Région de Kantō"><name sortKey="Fukushi, Shuetsu" sort="Fukushi, Shuetsu" uniqKey="Fukushi S" first="Shuetsu" last="Fukushi">Shuetsu Fukushi</name></region><name sortKey="Fukushi, Shuetsu" sort="Fukushi, Shuetsu" uniqKey="Fukushi S" first="Shuetsu" last="Fukushi">Shuetsu Fukushi</name><name sortKey="Fukushi, Shuetsu" sort="Fukushi, Shuetsu" uniqKey="Fukushi S" first="Shuetsu" last="Fukushi">Shuetsu Fukushi</name><name sortKey="Kurane, Ichiro" sort="Kurane, Ichiro" uniqKey="Kurane I" first="Ichiro" last="Kurane">Ichiro Kurane</name><name sortKey="Mizutani, Tetsuya" sort="Mizutani, Tetsuya" uniqKey="Mizutani T" first="Tetsuya" last="Mizutani">Tetsuya Mizutani</name><name sortKey="Morikawa, Shigeru" sort="Morikawa, Shigeru" uniqKey="Morikawa S" first="Shigeru" last="Morikawa">Shigeru Morikawa</name><name sortKey="Saijo, Masayuki" sort="Saijo, Masayuki" uniqKey="Saijo M" first="Masayuki" last="Saijo">Masayuki Saijo</name><name sortKey="Taguchi, Fumihiro" sort="Taguchi, Fumihiro" uniqKey="Taguchi F" first="Fumihiro" last="Taguchi">Fumihiro Taguchi</name><name sortKey="Tashiro, Masato" sort="Tashiro, Masato" uniqKey="Tashiro M" first="Masato" last="Tashiro">Masato Tashiro</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004285 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004285 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:E4E287284BC9B9C90C9C129E00637D69B0F35C14
|texte= Evaluation of a novel vesicular stomatitis virus pseudotype‐based assay for detection of neutralizing antibody responses to SARS‐CoV
}}
| This area was generated with Dilib version V0.6.33. |  |